公开(公告)号：US11414424B2

公开(公告)日：2022-08-16

申请号：US16557281

申请日：2019-08-30

申请人： Cytokinetics, Inc.

发明人： Chihyuan Chuang ,  Bradley P. Morgan ,  Mark Vanderwal ,  Luke W. Ashcraft ,  Kevin Lau

IPC分类号： C07D487/10 ,  A61P9/04 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  C07D491/107

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US09604965B2

公开(公告)日：2017-03-28

申请号：US14594274

申请日：2015-01-12

申请人： Cytokinetics, Inc.

发明人： Luke W. Ashcraft ,  Gustave Bergnes ,  Scott Collibee ,  Chihyuan Chuang ,  Jeff Gardina ,  Bradley P. Morgan ,  Alex R. Muci ,  Xiangping Qian ,  Jeffrey Warrington ,  Zhe Yang ,  Pu-Ping Lu ,  Antonio Romero

IPC分类号： A61K31/50 ,  C07D237/20 ,  C07D401/12 ,  C07D237/24 ,  C07D401/04 ,  C07D403/04 ,  C07D403/06 ,  C07D409/14 ,  C07D411/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/10 ,  C07D513/04 ,  C07D401/14 ,  C07D405/14

CPC分类号： A61K31/50 ,  A61K31/16 ,  A61K31/166 ,  C07D207/26 ,  C07D211/76 ,  C07D213/16 ,  C07D231/56 ,  C07D237/06 ,  C07D237/20 ,  C07D237/24 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D411/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/10 ,  C07D513/04 ,  Y02A50/465

摘要： Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11952381B2

公开(公告)日：2024-04-09

申请号：US17736895

申请日：2022-05-04

申请人： Cytokinetics, Inc.

发明人： Chihyuan Chuang ,  Bradley P. Morgan ,  Mark Vanderwal ,  Luke W. Ashcraft ,  Kevin Lau

IPC分类号： C07D487/10 ,  A61P9/04 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  C07D491/107

CPC分类号： C07D487/10 ,  A61P9/04 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  C07D491/107

摘要： Provided are compounds of Formula (I):




or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10076519B2

公开(公告)日：2018-09-18

申请号：US15463288

申请日：2017-03-20

申请人： CYTOKINETICS, INC.

发明人： Luke W. Ashcraft ,  Gustave Bergnes ,  Scott Collibee ,  Chihyuan Chuang ,  Jeff Gardina ,  Bradley P. Morgan ,  Alex R. Muci ,  Xiangping Qian ,  Jeffrey Warrington ,  Zhe Yang ,  Pu-Ping Lu ,  Antonio Romero

IPC分类号： A61K31/501 ,  C07D403/02 ,  A61K31/50 ,  C07D237/06 ,  C07D231/56 ,  A61K31/16 ,  A61K31/166 ,  C07D213/16 ,  C07D207/26 ,  C07D211/76

CPC分类号： A61K31/50 ,  A61K31/16 ,  A61K31/166 ,  C07D207/26 ,  C07D211/76 ,  C07D213/16 ,  C07D231/56 ,  C07D237/06 ,  C07D237/20 ,  C07D237/24 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D411/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/10 ,  C07D513/04 ,  Y02A50/465

摘要： Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11472796B2

公开(公告)日：2022-10-18

申请号：US17013472

申请日：2020-09-04

申请人： Cytokinetics, Inc.

发明人： Chihyuan Chuang ,  Bradley P. Morgan ,  Mark Vanderwal ,  Wenyue Wang ,  Luke W. Ashcraft

IPC分类号： C07D413/14 ,  A61K31/4245 ,  C07D413/12 ,  A61P9/00 ,  C07D271/06 ,  C07D413/10 ,  C07F5/02 ,  C07D413/04 ,  C07D403/12 ,  C07D417/12 ,  C07D401/12 ,  A61P9/04 ,  C07D231/14

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11919909B2

公开(公告)日：2024-03-05

申请号：US17685778

申请日：2022-03-03

申请人： Cytokinetics, Inc.

发明人： Bradley P. Morgan ,  Chihyuan Chuang ,  Luke W. Ashcraft ,  Justin Ho ,  Alfredo Garcia

IPC分类号： C07D487/10 ,  A61P9/04

CPC分类号： C07D487/10 ,  A61P9/04

摘要： Provided are compounds of Formula (I):




or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

公开(公告)号：US09994528B2

公开(公告)日：2018-06-12

申请号：US14823605

申请日：2015-08-11

申请人： Cytokinetics, Inc.

发明人： Luke W. Ashcraft ,  Gustave Bergnes ,  Scott Collibee ,  Chihyuan Chuang ,  Jeff Gardina ,  Bradley P. Morgan ,  Alex R Muci ,  Xiangping Qian ,  Antonio Romero ,  Jeffrey Warrington ,  Zhe Yang

IPC分类号： C07D213/74 ,  C07D213/75 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14 ,  C07D417/04 ,  C07D403/04 ,  A61K31/44 ,  A61K31/4427 ,  A61P21/00 ,  A61P21/04 ,  C07D213/78 ,  C07D213/82 ,  C07D215/48 ,  C07D253/07 ,  C07D215/38 ,  C07D403/10

CPC分类号： C07D213/74 ,  C07D213/75 ,  C07D213/78 ,  C07D213/82 ,  C07D215/38 ,  C07D215/48 ,  C07D253/07 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D417/04 ,  C07D417/14

摘要： Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.